Exploring the Mechanism of CYP3A4 Inactivation by Lapatinib Through In Vitro Metabolite Char.
Presented by: Joanna Barbara, Ph.D.
Metabolism-dependent inhibition of cytochrome P450 enzymes has the potential to cause clinically-relevant drug-drug interactions. Alkylamine drugs are known for their propensity to cause CYP inhibition by formation of a metabolite that binds quasi-irreversibly to the ferrous heme iron of the enzyme. The secondary alkylamine drug lapatinib has been linked both to drug-induced liver injury and quasi-irreversible inhibition of CYP3A4. In the present study, in vitro techniques to probe reversibility of enzyme inactivation were combined with metabolite profiling by high-resolution liquid chromatography with accurate mass spectrometry to explore the mechanism of CYP3A4 inactivation associated with lapatinib metabolism.
Key concepts discussed in this webinar will include:
- Insight into metabolism-dependent CYP inhibition by alkylamines
- Utility of in vitro reversibility assays
- Mechanism of CYP3A4 inactivation by the tyrosine kinase inhibitor lapatinib
What topic would you like to hear about?
Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to
